Literature DB >> 24025519

The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia.

John R Srigley1, Brett Delahunt, John N Eble, Lars Egevad, Jonathan I Epstein, David Grignon, Ondrej Hes, Holger Moch, Rodolfo Montironi, Satish K Tickoo, Ming Zhou, Pedram Argani.   

Abstract

The classification working group of the International Society of Urological Pathology consensus conference on renal neoplasia was in charge of making recommendations regarding additions and changes to the current World Health Organization Classification of Renal Tumors (2004). Members of the group performed an exhaustive literature review, assessed the results of the preconference survey and participated in the consensus conference discussion and polling activities. On the basis of the above inputs, there was consensus that 5 entities should be recognized as new distinct epithelial tumors within the classification system: tubulocystic renal cell carcinoma (RCC), acquired cystic disease-associated RCC, clear cell (tubulo) papillary RCC, the MiT family translocation RCCs (in particular t(6;11) RCC), and hereditary leiomyomatosis RCC syndrome-associated RCC. In addition, there are 3 rare carcinomas that were considered as emerging or provisional new entities: thyroid-like follicular RCC; succinate dehydrogenase B deficiency-associated RCC; and ALK translocation RCC. Further reports of these entities are required to better understand the nature and behavior of these highly unusual tumors. There were a number of new concepts and suggested modifications to the existing World Health Organization 2004 categories. Within the clear cell RCC group, it was agreed upon that multicystic clear cell RCC is best considered as a neoplasm of low malignant potential. There was agreement that subtyping of papillary RCC is of value and that the oncocytic variant of papillary RCC should not be considered as a distinct entity. The hybrid oncocytic chromophobe tumor, which is an indolent tumor that occurs in 3 settings, namely Birt-Hogg-Dubé Syndrome, renal oncocytosis, and as a sporadic neoplasm, was placed, for the time being, within the chromophobe RCC category. Recent advances related to collecting duct carcinoma, renal medullary carcinoma, and mucinous spindle cell and tubular RCC were elucidated. Outside of the epithelial category, advances in our understanding of angiomyolipoma, including the epithelioid and epithelial cystic variants, were considered. In addition, the apparent relationship between cystic nephroma and mixed epithelial and stromal tumor was discussed, with the consensus that these tumors form a spectrum of neoplasia. Finally, it was thought that the synovial sarcoma should be removed from the mixed epithelial and mesenchymal category and placed within the sarcoma group. The new classification is to be referred to as the International Society of Urological Pathology Vancouver Classification of Renal Neoplasia.

Entities:  

Mesh:

Year:  2013        PMID: 24025519     DOI: 10.1097/PAS.0b013e318299f2d1

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  270 in total

1.  Renal cell carcinoma: the search for a reliable biomarker.

Authors:  Nicholas J Farber; Christopher J Kim; Parth K Modi; Jane D Hon; Evita T Sadimin; Eric A Singer
Journal:  Transl Cancer Res       Date:  2017-06       Impact factor: 1.241

2.  [Vancouver classification of renal tumors: Recommendations of the 2012 consensus conference of the International Society of Urological Pathology (ISUP)].

Authors:  G Kristiansen; B Delahunt; J R Srigley; C Lüders; J-M Lunkenheimer; H Gevensleben; T Thiesler; R Montironi; L Egevad
Journal:  Pathologe       Date:  2015-05       Impact factor: 1.011

3.  Paediatrics: Towards evidence-based management of paediatric RCC.

Authors:  Filippo Spreafico
Journal:  Nat Rev Urol       Date:  2015-07-07       Impact factor: 14.432

Review 4.  The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.

Authors:  Tamina Seeger-Nukpezah; Daniel M Geynisman; Anna S Nikonova; Thomas Benzing; Erica A Golemis
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

Review 5.  A suggestion for pathological grossing and reporting based on prognostic indicators of malignancies from a pooled analysis of renal epithelioid angiomyolipoma.

Authors:  Shan Zheng; Xin-gang Bi; Qing-kun Song; Zheng Yuan; Lei Guo; Hongtu Zhang; Jian-hui Ma
Journal:  Int Urol Nephrol       Date:  2015-08-15       Impact factor: 2.370

6.  Tubulocystic Renal Cell Carcinoma in Young Adult.

Authors:  Abhishek Laddha; Amrutha Thomas; M R Bindhu; Ginil Kumar Pooleri
Journal:  Indian J Surg Oncol       Date:  2020-06-27

7.  Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion: A case report.

Authors:  Xiang Pan; Jing Quan; Liwen Zhao; Wenhua Li; Benlin Wei; Shangqi Yang; Yongqing Lai
Journal:  Mol Clin Oncol       Date:  2017-11-13

8.  Clear cell papillary renal cell carcinoma with angiomyomatous stroma: a histological, immunohistochemical, and fluorescence in situ hybridization study.

Authors:  Borislav A Alexiev; Carrie Thomas; Ying S Zou
Journal:  Virchows Arch       Date:  2014-04-27       Impact factor: 4.064

9.  Tumor-suppressing effects of microRNA-429 in human renal cell carcinoma via the downregulation of Sp1.

Authors:  Deyao Wu; Xiaobing Niu; Huixing Pan; Yunfeng Zhou; Zichun Zhang; Ping Qu; Jian Zhou
Journal:  Oncol Lett       Date:  2016-08-05       Impact factor: 2.967

10.  Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival.

Authors:  Rene Mager; Siamak Daneshmand; Christopher P Evans; Joan Palou; Juan I Martínez-Salamanca; Viraj A Master; James M McKiernan; John A Libertino; Axel Haferkamp; Axel Haferkamp; Umberto Capitanio; Joaquín A Carballido; Venancio Chantada; Thomas Chromecki; Gaetano Ciancio; Siamak Daneshmand; Christopher P Evans; Paolo Gontero; Javier González; Markus Hohenfellner; William C Huang; Theresa M Koppie; John A Libertino; Estefanía Linares Espinós; Adam Lorentz; Juan I Martínez-Salamanca; Viraj A Master; James M McKiernan; Francesco Montorsi; Giacomo Novara; Padraic O'Malley; Sascha Pahernik; Joan Palou; José Luis Pontones Moreno; Raj S Pruthi; Oscar Rodriguez Faba; Paul Russo; Douglas S Scherr; Shahrokh F Shariat; Martin Spahn; Carlo Terrone; Derya Tilki; Dario Vázquez-Martul; Cesar Vera Donoso; Daniel Vergho; Eric M Wallen; Richard Zigeuner
Journal:  J Surg Oncol       Date:  2016-08-26       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.